GRN and frontotemporal dementia: Preliminary results, released in 2024, from two participants in the phase 1/2 ASPIRE-FTD trial—the first human study of AVB-101, a gene therapy that also targets the GRN mutation—suggest acceptable safety and tolerability [33].